This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Macrophages and Tumor Necrosis Factor in Toxic Epidermal Necrolysis

Philippe Paquet, MD; Arjen Nikkels, MD; Jorge E. Arrese, MD; Alain Vanderkelen, MD; Gerald E. Piérard, MD

Arch Dermatol. 1994;130(5):605-608.

Abstract
Background
We studied the immunopathologic characteristics of five cases of toxic epidermal necrolysis by using a large panel of antibodies.

Observations
The pattern and amount of the inflammatory cell infiltrate varied according to the stage of the disease. The main constant feature was the prominent involvement of the monocyte-macrophage lineage, including factor XIIIa⁺ HLA-DR⁺ dendrocytes and CD68⁺ Mac 387⁺ macrophages, before and during the epidermal ne- crosis. The number of CD4⁺ and CD8⁺ lymphocytes was comparatively small. This was associated with a dense labeling of the epidermis for tumor necrosis factor a.

Conclusions
Cells of the monocyte-macrophage lineage largely outnumber lymphocytes in the lesions of toxic epidermal necrolysis. Tumor necrosis factor a is likely a major cytokine that is responsible for necrosis.

(Arch Dermatol. 1994;130:605-608)

Author Affiliations
From the Department of Dermatopathology, University of Liège (Belgium) (Drs Paquet, Nikkels, Arrese, and Piérard) and the Center for Burn Patients, Brussels (Belgium) Military Hospital (Dr Vanderkelen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of toxic epidermal necrolysis and related syndromes
Mukasa and Craven
Postgrad. Med. J. 2008;84:60-65.
ABSTRACT | FULL TEXT  

Early pathological features of the cornea in toxic epidermal necrolysis
Williams et al.
Br J Ophthalmol 2007;91:1129-1132.
ABSTRACT | FULL TEXT  

Cell-Mediated Immunologic Mechanism and Severity of TEN
Faye et al.
Arch Dermatol 2005;141:775-776.
FULL TEXT  

Cutaneous Drug Eruption to Infliximab: Report of 4 Cases With an Interface Dermatitis Pattern
Vergara et al.
Arch Dermatol 2002;138:1258-1259.
FULL TEXT  

Immune Mechanisms of TEN
Journal Watch Dermatology 1994;1994:10-10.
FULL TEXT